Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. more
Time Frame | KYTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.85% | 0.49% | -0.42% |
1-Month Return | -24.84% | -3.1% | -2.2% |
3-Month Return | -24.18% | -8.59% | 2.38% |
6-Month Return | -59.22% | -4.57% | 5.1% |
1-Year Return | -88.5% | -0.94% | 23.79% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | 5.66M | 7.03M | - | [{"date":"2021-12-31","value":80.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | 586.00K | 1.05M | 1.71M | [{"date":"2021-12-31","value":34.33,"profit":true},{"date":"2022-12-31","value":61.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Profit | 5.07M | 5.97M | (1.71M) | [{"date":"2021-12-31","value":84.87,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-28.57,"profit":false}] | ||
Gross Margin | 89.64% | 85.04% | (Infinity%) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.87,"profit":true},{"date":"2023-12-31","value":null,"profit":false}] | ||
Operating Expenses | 32.00M | 36.41M | 62.41M | [{"date":"2021-12-31","value":51.28,"profit":true},{"date":"2022-12-31","value":58.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (26.35M) | (29.38M) | (62.41M) | [{"date":"2021-12-31","value":-2634600000,"profit":false},{"date":"2022-12-31","value":-2938400000,"profit":false},{"date":"2023-12-31","value":-6240600000,"profit":false}] | ||
Total Non-Operating Income/Expense | (6.00K) | 991.00K | 4.13M | [{"date":"2021-12-31","value":-0.15,"profit":false},{"date":"2022-12-31","value":23.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Pre-Tax Income | (26.35M) | (28.89M) | (60.37M) | [{"date":"2021-12-31","value":-2635000000,"profit":false},{"date":"2022-12-31","value":-2889300000,"profit":false},{"date":"2023-12-31","value":-6036600000,"profit":false}] | ||
Income Taxes | 1.00K | 56.00K | 132.00K | [{"date":"2021-12-31","value":0.76,"profit":true},{"date":"2022-12-31","value":42.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income After Taxes | (26.35M) | (28.95M) | (60.50M) | [{"date":"2021-12-31","value":-2635100000,"profit":false},{"date":"2022-12-31","value":-2894900000,"profit":false},{"date":"2023-12-31","value":-6049800000,"profit":false}] | ||
Income From Continuous Operations | (26.35M) | (28.89M) | (60.37M) | [{"date":"2021-12-31","value":-2635000000,"profit":false},{"date":"2022-12-31","value":-2889300000,"profit":false},{"date":"2023-12-31","value":-6036600000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (26.35M) | (28.89M) | (60.37M) | [{"date":"2021-12-31","value":-2635000000,"profit":false},{"date":"2022-12-31","value":-2889300000,"profit":false},{"date":"2023-12-31","value":-6036600000,"profit":false}] | ||
EPS (Diluted) | - | - | (26.86) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-2686,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
KYTX | |
---|---|
Cash Ratio | 10.38 |
Current Ratio | 10.50 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KYTX | |
---|---|
ROA (LTM) | -35.60% |
ROE (LTM) | -59.58% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KYTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KYTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.54 |
Price/FCF | NM |
EV/R | 3341.48 |
EV/Ebitda | NM |
Kyverna Therapeutics, Inc. Common Stock (KYTX) share price today is $3.45
Yes, Indians can buy shares of Kyverna Therapeutics, Inc. Common Stock (KYTX) on Vested. To buy Kyverna Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KYTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kyverna Therapeutics, Inc. Common Stock (KYTX) via the Vested app. You can start investing in Kyverna Therapeutics, Inc. Common Stock (KYTX) with a minimum investment of $1.
You can invest in shares of Kyverna Therapeutics, Inc. Common Stock (KYTX) via Vested in three simple steps:
The 52-week high price of Kyverna Therapeutics, Inc. Common Stock (KYTX) is $35.06. The 52-week low price of Kyverna Therapeutics, Inc. Common Stock (KYTX) is $3.41.
The price-to-earnings (P/E) ratio of Kyverna Therapeutics, Inc. Common Stock (KYTX) is
The price-to-book (P/B) ratio of Kyverna Therapeutics, Inc. Common Stock (KYTX) is 0.54
The dividend yield of Kyverna Therapeutics, Inc. Common Stock (KYTX) is 0.00%
The market capitalization of Kyverna Therapeutics, Inc. Common Stock (KYTX) is $148.94M
The stock symbol (or ticker) of Kyverna Therapeutics, Inc. Common Stock is KYTX